OTLK - Outlook Therapeutics • Financials

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
09/2016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2023	0	-53	-	0%	L	-14	L	-23	-	-49	0	49	-49	0	0	-	-
09/2024	0	-72	-	0%	L	-73	L	-15	-	-74	0	60	-74	0	0	-	-
09/2025	1	-67	-	L	L	-32	L	-8	-	-61	0	45	-61	0	0	-	-

To see all financials—including updated, you must be Premium.